Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma

Ashutosh D. Wechalekar, C. I. Chen, D. Sutton, D. Reece, M. Voralia, Alexander Keith Stewart

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Thalidomide at doses >200 mg has 100% grade 1-2 and 25% grade 3-4 toxicities requiring discontinuation. We report a retrospective study of relapsed myeloma patients treated with thalidomide 200 mg with no dose escalation. Thirty patients were identified; 43% of patients responded with paraprotein decline >75% - 2 (6%), 50-75% - 7 (23%), 25-50% - 4 (14%) and 2 (6%) were stable. All five patients with 13q deletion responded. Only 54% reported grade 1-2 toxicities (none reporting > grade 2) with 5 (17%) discontinuing treatment due to toxicity. Thalidomide 200 mg daily with no dose escalation appears as effective and better tolerated than escalated doses for relapsed myeloma patients.

Original languageEnglish (US)
Pages (from-to)1147-1149
Number of pages3
JournalLeukemia and Lymphoma
Volume44
Issue number7
DOIs
StatePublished - Jul 1 2003
Externally publishedYes

Fingerprint

Thalidomide
Multiple Myeloma
Paraproteins
Retrospective Studies

Keywords

  • Dose escalation
  • Efficacy
  • Intermediate dose
  • Thalidomide

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma. / Wechalekar, Ashutosh D.; Chen, C. I.; Sutton, D.; Reece, D.; Voralia, M.; Stewart, Alexander Keith.

In: Leukemia and Lymphoma, Vol. 44, No. 7, 01.07.2003, p. 1147-1149.

Research output: Contribution to journalArticle

Wechalekar, Ashutosh D. ; Chen, C. I. ; Sutton, D. ; Reece, D. ; Voralia, M. ; Stewart, Alexander Keith. / Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma. In: Leukemia and Lymphoma. 2003 ; Vol. 44, No. 7. pp. 1147-1149.
@article{4e24bb3615fe4ad6a983dac78a5b9f1e,
title = "Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma",
abstract = "Thalidomide at doses >200 mg has 100{\%} grade 1-2 and 25{\%} grade 3-4 toxicities requiring discontinuation. We report a retrospective study of relapsed myeloma patients treated with thalidomide 200 mg with no dose escalation. Thirty patients were identified; 43{\%} of patients responded with paraprotein decline >75{\%} - 2 (6{\%}), 50-75{\%} - 7 (23{\%}), 25-50{\%} - 4 (14{\%}) and 2 (6{\%}) were stable. All five patients with 13q deletion responded. Only 54{\%} reported grade 1-2 toxicities (none reporting > grade 2) with 5 (17{\%}) discontinuing treatment due to toxicity. Thalidomide 200 mg daily with no dose escalation appears as effective and better tolerated than escalated doses for relapsed myeloma patients.",
keywords = "Dose escalation, Efficacy, Intermediate dose, Thalidomide",
author = "Wechalekar, {Ashutosh D.} and Chen, {C. I.} and D. Sutton and D. Reece and M. Voralia and Stewart, {Alexander Keith}",
year = "2003",
month = "7",
day = "1",
doi = "10.1080/1042819031000067918",
language = "English (US)",
volume = "44",
pages = "1147--1149",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma

AU - Wechalekar, Ashutosh D.

AU - Chen, C. I.

AU - Sutton, D.

AU - Reece, D.

AU - Voralia, M.

AU - Stewart, Alexander Keith

PY - 2003/7/1

Y1 - 2003/7/1

N2 - Thalidomide at doses >200 mg has 100% grade 1-2 and 25% grade 3-4 toxicities requiring discontinuation. We report a retrospective study of relapsed myeloma patients treated with thalidomide 200 mg with no dose escalation. Thirty patients were identified; 43% of patients responded with paraprotein decline >75% - 2 (6%), 50-75% - 7 (23%), 25-50% - 4 (14%) and 2 (6%) were stable. All five patients with 13q deletion responded. Only 54% reported grade 1-2 toxicities (none reporting > grade 2) with 5 (17%) discontinuing treatment due to toxicity. Thalidomide 200 mg daily with no dose escalation appears as effective and better tolerated than escalated doses for relapsed myeloma patients.

AB - Thalidomide at doses >200 mg has 100% grade 1-2 and 25% grade 3-4 toxicities requiring discontinuation. We report a retrospective study of relapsed myeloma patients treated with thalidomide 200 mg with no dose escalation. Thirty patients were identified; 43% of patients responded with paraprotein decline >75% - 2 (6%), 50-75% - 7 (23%), 25-50% - 4 (14%) and 2 (6%) were stable. All five patients with 13q deletion responded. Only 54% reported grade 1-2 toxicities (none reporting > grade 2) with 5 (17%) discontinuing treatment due to toxicity. Thalidomide 200 mg daily with no dose escalation appears as effective and better tolerated than escalated doses for relapsed myeloma patients.

KW - Dose escalation

KW - Efficacy

KW - Intermediate dose

KW - Thalidomide

UR - http://www.scopus.com/inward/record.url?scp=0038324297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038324297&partnerID=8YFLogxK

U2 - 10.1080/1042819031000067918

DO - 10.1080/1042819031000067918

M3 - Article

VL - 44

SP - 1147

EP - 1149

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 7

ER -